

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2825.2025-001APPLICATION NO.
10/007,781INFORMATION DISCLOSURE CITATION
IN AN APPLICATIONAPPLICANT
Stacey Bolk, et al.FILING DATE
November 13, 2001CONFIRMATION
1826GROUP
1825

January 15, 2003

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
9	AA	5,750,502	12 May 98	Jessell, et al.
9	AB	5,279,966	18 Jan 94	Jessell, et al.

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

9	AR	Polymeropoulos, M.H., et al., "Dinucleotide Repeat Polymorphism at the Human Thrombospondin Gene (THBS1)," <i>Nucleic Acids Research</i> , 18(24):7467 (1990).					
1	AS	Wang, D.G., et al., "Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome," <i>Science</i> , 280:1077-1082 (1998).					
	AT	Fan, J., et al., "Genetic Mapping: Finding and Analyzing Single-Nucleotide Polymorphisms With High-Density DNA Arrays," <i>American Journal of Human Genetics</i> , 61 (4th suppl.):1601 (1997) (Abstract only).					
	AU	Tang, S., et al., "Enhancement of Endothelial Cell Migration and Angiogenesis In Vitro by a Novel Gene Product," <i>Circulation</i> , American Heart Association, Abstract No. 3821 from the 71 st Scientific Sessions, Dallas, Texas, (November 8-11, 1998).					
	AV	Kalka, C., et al., "Novel Genes Containing the Thrombospondin Type 1 Domain Suppress the Development of Angiogenesis in an in-vivo Model of Peripheral Vascular Ischemia," <i>Circulation</i> , American Heart Association, Abstract No. 3825 from the 71 st Scientific Sessions, Dallas, Texas, (November 8-11, 1998).					
	AW	Lange, L.A., et al., "Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:418-423 (2002).					
	AX	Accession No. AF102887, <i>Mus musculus</i> Thrombospondin-4 mRNA, October 19, 1999.					
	AY	Accession No. X89963, <i>R. norvegicus</i> mRNA TSP-4 protein, January 29, 1998.					
✓	AZ	Accession No. Z19091, <i>X. laevis</i> encoding thrombospondin-4, June 22, 1993.					

EXAMINER

Jeanne Sonaepe

DATE CONSIDERED

7/17/03

PIPE
JAN 21 2003
TRADEMARK

RECEIVED
TECH CENTER 100-330
JAN 22 2003

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2825.2025-001APPLICATION NO.
10/007,781INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

January 15, 2003

several sheets if necessary)

APPLICANT
Stacey Bolk, et al.FILING DATE
November 13, 2001CONFIRMATION NO.
1826

U.S. PATENT DOCUMENTS

EXAM-
INER
INI-
TIAL

DOCUMENT NUMBER

ISSUE DATE /
PUBLICATION DATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUB-
CLASSTRANSLATION
YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AR2

Kyriakides, T.R., "Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis," *J. Cell Biol.*, 140(2):419-430 (1998).

AS2

Yang, Z., et al., "Matricellular Proteins as Modulators of Cell-Matrix Interactions: Adhesive Defect in Thrombospondin 2-null Fibroblasts in a Consequence of Increased Levels of Matrix Metalloproteinase-2," *Mol. Biol. Cell*, 11(10):3353-3364 (2000).


AT2

Lawler, J., et al., "Characterization of Human Thrombospondin-4*," *J. Biol. Chem.*, 270(6): 2809-2814 (1995).

EXAMINER

DATE CONSIDERED

7/17/03



PTO 1449 REPRODUCED

ATTORNEY DOCKET NO.
2825.2025-001

APPLICATION NO.
10/007.781

**SUPPLEMENTAL INFORMATION DISCLOSURE
CITATION IN AN APPLICATION**

May 20, 2003

(Use several sheets if necessary)

APPLICANT
Stacey Bolk *et al.*

FILING DATE
November 13, 2001

CONFIRMATION NO.
1826

GROUP
1634

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ALJ2

Crawford, S.E., *et al.*, "Thrombospondin-1 Is a Major Activator of TGF- β 1 *In Vivo*," *Cell*, 93: 1159-1170 (1998).

EXAMINER

DATE CONSIDERED

Johanne Sonayk

7/17/03

☒ Applicants request that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 09/657,472, by Eric S. Lander, *et al.*, filed September 7, 2002, Docket No.: 2825.1027-001.

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☒ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.


It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,
HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By



Pamela A. Torpey
Registration No.: 45,736
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated: January 15, 2003